Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of Elagolix in Patients With Moderate to Severe Endometriosis-Associated Pain

NCT05648669 is registered in ClinicalTrials.gov with Qilu Pharmaceutical (Hainan) Co., Ltd. as lead sponsor.

NCT NCT05648669
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05648669 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of Elagolix in Patients With Moderate to Severe Endometriosis-Associated Pain
Lead sponsor
Qilu Pharmaceutical (Hainan) Co., Ltd.
Phase
Phase 3
Overall status
Unknown status
Start date
September 4, 2022
Completion date
February 29, 2024
Enrollment
336 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

endometriosis